论文部分内容阅读
1959年国外已有将胎肝细胞用于临床的报道.我国学者的研究表明,妊娠4～5月的人胎肝中存在着丰富的造血干细胞。胎肝造血干细胞的增殖能力,较之成年骨髓造血干细胞更强。并指出,胎肝是除骨髓之外的又一个造血干细胞来源.国内潘瑞彭等1963年首报用于治疗急性白血病和晚期癌症病人。此后,特别近几年,其临床应用的报道日增,治疗病种范围亦在扩大,而在治疗某些疾病方面,我国已走在世界之前列。本文主要就国内有关医学文献报告对胎肝细胞悬液的临床应用,特别是在治疗再生
1959, foreign countries have fetal liver cells for clinical reports.Our country’s scholars have shown that there are abundant hematopoietic stem cells in human fetal liver in pregnancy from April to May. Fetal liver hematopoietic stem cell proliferation, compared with adult bone marrow hematopoietic stem cells stronger. And pointed out that fetal liver is a bone marrow in addition to a source of hematopoietic stem cells.Pei Peng domestic first reported in 1963 for the treatment of acute leukemia and advanced cancer patients. Since then, especially in recent years, the coverage of its clinical application has been increasing, and the range of treatment diseases has also been expanding. As for the treatment of certain diseases, our country has taken the forefront in the world. This article mainly on the domestic medical literature on the clinical application of fetal liver cell suspension, especially in the treatment of regeneration